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activity in patients with end-stage renal disease
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Background: We conducted this study to determine the erythrocyte glucose-6-phosphate dehydrogenase (G6PD)
activity level in patients with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) and to determine
the effect of hemodialysis adequacy on G6PD activity levels and its impact on anemia.
Methods: Eighty-two patients (48 men and 34 women) receiving regular hemodialysis for ESRD through
arteriovenous fistulae for at least one year prior to the start of the study were enrolled in this study. G6PD activity
levels were measured in all patients and the average Kt/V was used as a parameter of HD adequacy. Patients were
divided into two groups according to Kt/V values. Group 1 included 45 patients with Kt/V˃1.2 (adequate HD), and
group 2 included 37 patients with Kt/V˂1.2 (inadequate HD). The average hemoglobin level and the weekly dose of
an erythropoietin-stimulating agent, epoetin alpha (ESA), for each patient were calculated for one year.
Results: The mean (SD) erythrocyte G6PD activity for all patients on hemodialysis was 7.64 ± 1.85 U/g Hb. Patients
who had received adequate hemodialysis had a significantly higher average erythrocyte G6PD (mean (SD) = 9.2 ±
0.7 U/g Hb) compared to patients who had inadequate hemodialysis (mean (SD) = 5.7 ± 0.7U/g Hb) (P-value <0.005).
The mean hemoglobin concentration was significantly higher in patients with adequate hemodialysis compared to
those with inadequate hemodialysis.
Conclusion: Our study demonstrated the beneficial effect of adequate hemodialysis in correcting anemia by
enhancing the erythrocyte G6PD activity in patients.
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Factors contributing to anemia in ESRD patients include
erythropoietin deficiency, blood loss, shortened red blood
cell (RBC) life span, vitamin deficiencies, iron deficiency,
and chronic inflammation [1,2]. The shortened RBC sur-
vival observed in uremic patients has been attributed
mainly to uremic toxins [3]. In patients with ESRD, there
is growing evidence that increased oxidative stress may
contribute to anemia, along with other factors such as* Correspondence: ayeshmahmoud@hotmail.com
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article, unless otherwise stated.erythropoietin-stimulating agent (ESA) resistance, malnu-
trition, and atherosclerosis [4].
Erythrocyte G6PD is the key enzyme in the hexose
monophosphate shunt (HMP). The HMP plays a signifi-
cant role in RBC antioxidant reactions and is the only
source of nicotinamide adenine dinucleotide phosphate
(NADPH), a molecule that is essential in maintaining
reduced glutathione (GSH) levels. In vitro studies have
shown that low-molecule uremic toxins methylguanidine
(MG) and guanidinosuccinic acid (GSA) have negative ef-
fects on the activity of erythrocyte G6PD in human RBCs
[5]. Several studies have shown decreased G6PD activity
in uremic patients. This decrease in erythrocyte G6PD ac-
tivity causes hemolysis, and likely plays a role in the
pathogenesis of anemia in patients with ESRD [4,6].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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measured by Kt/V have been shown to play an important
role in improving anemia and reducing the ESA dosage
required for anemia correction in patients with ESRD
[7-11]. This benefit may due to the correction of oxidative
stress, and the removal of molecules that inhibit erythro-
poiesis and erythrocyte G6PD activity [12]. This effect
may explain the beneficial effect of hemodialysis adequacy,
using Kt/Vas a parameter for the assessment of dialysis
adequacy, on anemia in patients with ESRD on mainten-
ance HD. However, there are no data available regarding
the effect of hemodialysis adequacy on the activity of
erythrocyte G6PD.
The Kt/V ratio is one parameter used for measurement
of the adequacy of dialysis treatment. In this expression K
is dialyzer clearance, expressed in mL/min, t indicates the
duration of the dialysis session, and V is the volume of
water the patient’s body. Clearance multiplied by time (Kt)
is a measure of the volume of fluid completely cleared of
urea during a single dialysis treatment.
We conducted this study to determine the G6PD ac-
tivity level in patients with ESRD on maintenance HD
and to study the effect of hemodialysis adequacy on
G6PD activity levels and its impact on anemia.
Methods
Patients
This study was performed over a period of one year in the
outpatient dialysis unit of King Abdullah University Hos-
pital, an 800-bed tertiary care center. Eighty-two patients
(48 men and 34 women) receiving regular hemodialysis
for ESRD through arteriovenous fistulae for at least one
year prior to the start of the study were enrolled in this
study. Information about the underlying cause of ESRD
and Kt/V average over a period of one year were obtained
from their dialysis unit records. The underlying causes of
ESRD were divided into two categories: diabetic nephrop-
athy in 39 patients, and non-diabetic nephropathy 43 pa-
tients. Patients underwent dialysis three times weekly with
sessions consistently four hours in duration. At the time
of enrollment, complete blood count with red cell indices,
reticulocyte percentage and count, liver function tests,
kidney function tests, serum ferritin, serum iron, serum
vitamin B12, and serum folate levels were measured in all
patients. Direct antiglobulin test, parathyroid hormone
level, and C-reactive protein (CRP) were also measured.
Patients were also screened for hepatitis B and C. Patients
were grouped in to 2 groups according to their Kt/V.
Group 1 included 45 patients with Kt/V˃1.2 (adequate
HD) and group 2 included 37 patients with Kt/V˃1.2 (in-
adequate HD). All patients underwent ultrasound (US)
examination of the kidneys to evaluate for cystic lesions.
The Human Research Committee at Jordan University
of Science and Technology and the Institutional ReviewBoard of King Abdullah University approved this study.
All patients signed written informed consent prior to
their participation.
Inclusion and exclusion criteria
Patients with ESRD on regular maintenance hemodialysis
for at least one year prior to the start of the study, were in-
cluded in this study. All patients were iron replete and had
received ESA for at least four months prior to the start of
the study. Patients were excluded from this study if they had
received a blood transfusion in the four months prior to the
start of the study. Patients with congenital polycystic kidney
diseases and acquired cystic kidney diseases detected by US
imaging were excluded. Patients with any known blood
disorders including G6PD deficiency, hemoglobinopathy,
elevated white blood cell count >12 × 109/L and platelet
count >600 × 109/L were excluded. Patients with anemia not
due to ESRD including iron deficiency, vitamin B12 defi-
ciency, and folate deficiency were also excluded. Patients on
maintenance HD with evidence of inflammation (as sug-
gested by high CRP levels) were excluded from this study.
Additionally, patients with hepatic disease, respiratory dis-
ease, and those taking antioxidant vitamin and fish oil sup-
plements were excluded from this study.
ESA
All patients with ESRD on maintenance HD included in
the study were on the same type ESA administered on a
per kilogram basis. The average weekly dose over the
course of one year was calculated for each patient.
Erythrocyte G6PD activity level
Six ml of venous blood was collected from each patient just
before the HD session to measure average erythrocyte
G6PD activity. Quantitative assay of erythrocyte G6PD level
was performed on freshly prepared hemolysates using a
commercial kit (Trinity Biotech USA). This method em-
ploys a modification of the spectrophotometric method.
The assay of erythrocytes G6PD activity was begun with a
determination of the hemoglobin level (Hb g/dl) in an eth-
ylenediaminetetraacetic acid (EDTA) blood sample. The
hemolysate samples were subjected to RBC enzyme analysis
as described by Beutler et al. [13]. G6PD activity in the
hemolysate was measured by spectrophotometric assay
(Beckman Coulter, CX9 USA) at 340 nm and at 37C within
0–19 min after the hemolysate was introduced into the
CX9 system. The calculated G6PD activity U/L was con-








g HBb ¼ y UGHBb as foll
The normal value was established by measuring erythro-
cyte G6PD activity in the control group. The normal value
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trol ± SD.
Kt/V and dialysis modality
Standard HD had been provided for all patients using HD
instruments (Fresenius 4000H machines) with online meas-
urement capabilities. All patients used synthetic Polysulfone
F series high performance steam capillary dialysis designed
for single use (Fresenius medical, USA). Patients were con-
sidered to have adequate hemodialysis if their Kt/V ratio
was >1.2 [14].
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Science (SPSS) software. The data were
described using means and standard deviations. Two-
tailed t test was used to determine the statistical signifi-
cance of the differences between two means. Fisher Exact
test was used to compare the difference between two pro-




This study included 82 patients [48 male (58.5%) and 34
female (41.5%)] with a mean (SD) age of 50.3 ± 20.7 years.
The demographic and clinical characteristics of patients
shown in Table 1. All patients were treated with the same
type ESA (epoetin alpha) according to body weight.
G6PD level and adequacy of dialysis
Table 2 shows the laboratory and clinical characteristics of
the patients based on the adequacy of hemodialysis as mea-
sured by Kt/V. The mean (SD) erythrocyte G6PD activity
for all patients on hemodialysis was 7.64 ± 1.85 U/g Hb.
Patients who had received adequate hemodialysis had a
significantly higher average erythrocyte G6PD (meanTable 1 The demographic and clinical characteristics of
82 patients receiving regular hemodialysis for ESRD




Age (year) 50.32 ± 20.73
Diabetes mellitus, n (%)
Yes 39 (47.6)
No 43 (52.4)
Hemoglobin (Hb) before initiation of HD (g/dL) 9.33 ± 1.05
Hemoglobin at end of study (g/dL) 11.78 ± 2.05
G6PD activity level at end of study (U/g Hb) 7.64 ± 1.85
Serum creatinine level (μmol/L) 758.45 ± 280.3(SD) = 9.2 ± 0.7 U/g Hb) compared to patients who had
inadequate hemodialysis (mean (SD) = 5.7 ± 0.7U/g Hb)
(P-value <0.005). There were no significant differences in
the prevalence of diabetes between patients with adequate
hemodialysis and those with inadequate hemodialysis. The
mean hemoglobin concentration was significantly higher in
patients with adequate hemodialysis compared to those
with inadequate hemodialysis. The mean average ESA dose
was lower in patients with adequate HD compared with
those with inadequate HD.
Discussion
This study showed that there was significant difference
in the erythrocyte G6PD activity level in patients with
adequate HD (Kt/V ≥1.2) compared to those with inad-
equate HD (Kt/V ˃1.2). Patients with adequate HD had
significantly higher erythrocyte G6PD activity and
hemoglobin levels compared to patients who received
inadequate HD. Despite prior studies showing lower
G6PD activity in diabetes mellitus [15-17], the preva-
lence of diabetes was not significantly different between
our two groups. Therefore, diabetes was unlikely to be a
confounding factor in the association between adequate
hemodialysis and G6PD activity levels. Interestingly, pa-
tients with adequate HD required a lower average weekly
dose of ESA to reach the target hemoglobin level over
the one year of the study than those with inadequate
HD. This supports the theory that hemodialysis ad-
equacy is the main factor responsible for higher G6PD
activity levels in these patients. This is in agreement with
other studies that have demonstrated that patients with
adequate HD had a better response to ESA than those
patients with inadequate HD [8,10].
Adequate HD in our study has been shown to be asso-
ciated with higher hemoglobin levels in patients on
maintenance HD than patients with inadequate HD, al-
though patients with inadequate HD had a higher reticu-
locyte percentage compared to patients with adequate
HD. Despite the fact that reticulocytes had higher G6PD
activity than older RBCs, patients with inadequate HD
still had lower G6PD activity levels. Moreover, one need
to consider that the increased reticulocyte activity in the
low Kt/V group compared to the high Kt/V group might
indicate adequate response to ESA. Then the decreased
Hb concentration in low Kt/V group could be explained
by decreased RBC lifespan.
The reduced activity of G6PD might be explained by the
high level of oxidized glutathione (GSSG) which is found
to be increased in the plasma of patients with chronic
renal failure compared to those with normal renal func-
tion. Costagliola et al. [18] reported that high levels of
GSSG in the plasma could exert important effects on
RBCs including inhibition of G6PD activity. With the sub-
sequent alteration of the glutathione system, GSSG readily
Table 2 The laboratory and clinical characteristics of the patients based on the adequacy of hemodialysis as measured
by Kt/V
Variable Adequate hemodialysis N = 45 Inadequate hemodialysis N = 37 P-value
Kt/V 1.31 ± 0.96 0.98 ± 0.09 0.046
Age, years 49.8 ± 20.6 57.9 ± 16.6 0.057
ESA (epoetin alpha) (IU/Week) 7176.4 ± 2823.6 9155.0 ± 2844.3 0.002
Serum creatinine (μmol/L) 778.0 ± 274.1 776.3 ± 277.0 0.978
G6PD activity level (U/g Hb) 9.2 ± 0.7 5.7 ± 0.7 <0.005
Diabetic patients, n (%) 21 (46.7%) 18 (48.7%) 0.965
Hematocrit 37.0 ± 6.0 28.4 ± 7.2 <0.005
Hemoglobin (g/dL) 12.0 ± 2.0 9.5 ± 2.4 <0.005
Reticulocyte count, % 1.9 ± 0.10 2.2 ± 0.3 <0.005
HD duration (months) 18,06 ± 14.66 15 ± 14.28 0.486
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mixed disulfides, with consequent protein aggregation and
precipitation. Several studies have shown improvement in
hemoglobin levels in patients with maintenance HD treated
by glutathione reduction, this supports our finding of de-
creased G6PD activity in patients with ESRD on mainten-
ance HD [19].
In our study, we used the same dialysis membrane dur-
ing HD in all patients in order to separate the effect of
HD adequacy on G6PD activity from a potential mem-
brane effect on G6PD activity [20]. In addition, in our
study the difference in mean age between the two groups
is marginally significant (P-value = .057), and this might
have contributed to the observed difference in G6PD ac-
tivity levels. Aging has been associated with a decrease in
the G6PD activity level [21], and the inadequate HD group
had a higher mean age (57.9 ± 16.6 years) compared to the
adequate HD group (49.8 ± 20.6 years).
Our study demonstrates that hemodialysis adequacy
plays an important role in correcting anemia in patients
with ESRD on regular HD by enhancing the activity of
erythrocyte G6PD activity. Hemodialysis per se, without
administration of ESA, improves anemia, this suggest
that hemodialysis exerts its effect by removal of inhibi-
tors of erythropoiesis [7,22]. In our study, we suggest
that hemodialysis, by removal of G6PD enzyme inhibi-
tors, plays an important role in the improvement of
anemia in patients with ESRD as suggested by previous
studies [4,6,12].
One limitation of this study is that erythrocyte G6PD
activity level was not measured at the time of ESRD diag-
nosis and prior to the institution of HD. Dialyzer mem-
branes have been shown to have antioxidant effects, and
may have had an effect on our results. Another limitation
of this study is that no patients with inadequate HD had
their G6PD activity measured after increasing the dialysis
intensity to an adequate HD level (Kt/V ˃1.2). This was
not feasible as patients on regular HD have a fixed timeand duration for their dialysis session, therefore the rea-
sons for dialysis inadequacy are difficult to correct. More-
over, other markers of intravascular hemolysis such as
haptoglobin or LDH were not available for analysis.
Conclusion
Our study demonstrated the beneficial effect of ad-
equate hemodialysis in correcting anemia by enhancing
the erythrocyte G6PD activity in patients. Improving
anemia in patients with ESRD may result in reduction
of ESA requirements, and may improve the general sta-
tus of ESRD patients by reducing the morbidity associ-
ated with anemia. Additionally, enhancing the activity of
a major antioxidant enzyme, such as G6PD, may result
in a reduction of complications secondary to increased
oxidative stress in patients with ESRD.
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